Saturday 17 October 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.
49.30
2.22
−4.31%
Follow CRSP
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | 2 | 6 | 3 | 7 | 2 | 4 | 3 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 54.87 | 0.00 | 15.19 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.50 | 6.51 | 7.67 | 16.78 | 36.99 | 11.48 | 4.57 | 8.76 | 5.89 | 7.04 |
P/S ratio |
53.41 | 24.59 | 438.65 | 11.44 | 14,043.96 | 6.29 | 2,660.79 | 14.10 | 88.98 | 1,343.49 |
Altman Z″-Score (non-manufacturers) |
5.98 | 4.91 | 6.01 | 13.08 | 14.17 | 13.31 | 7.18 | 8.86 | 8.57 | 6.42 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 66.27 | 0.00 | 12.59 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(14.20) | (67.93) | (48.30) | 981.34 | (124.34) | (66.89) | (28.13) | (54.47) | (66.37) | (50.95) |
Beneish M-Score |
15.89 | 3.19 | (7.56) | 80.41 | 438.23 | 1,131.22 | 25,201.83 | 272.49 | (4.94) | — |
P/B ratio |
1.18 | 5.37 | 3.49 | 3.53 | 6.07 | 2.40 | 1.70 | 2.78 | 1.72 | 2.45 |
Price to Tangible BV |
1.19 | 5.38 | 3.50 | 3.53 | 6.07 | 2.40 | 1.70 | 2.78 | 1.72 | 2.45 |
EV/Sales |
(7.69) | 18.74 | 292.47 | 8.33 | 11,762.55 | 3.92 | 1,335.82 | 10.15 | 44.05 | 845.25 |
EV/EBITDA |
0.59 | 0.00 | 0.00 | 46.89 | 0.00 | 9.17 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.72 | (10.96) | (9.49) | 42.58 | (35.48) | 6.66 | (3.23) | (14.47) | (11.51) | (8.60) |
EV/FCF |
0.68 | (9.86) | (9.23) | 48.27 | (32.94) | 7.85 | (3.00) | (13.96) | (11.36) | (8.58) |
Quick Ratio |
14.49 | 16.70 | 16.46 | 16.53 | 17.93 | 19.85 | 15.08 | 17.41 | 21.97 | 13.25 |
Current Ratio |
14.56 | 17.12 | 16.81 | 17.29 | 18.21 | 20.17 | 15.30 | 17.54 | 22.07 | 13.32 |
Net Debt/EBITDA |
4.69 | 3.89 | 2.94 | (18.34) | 4.92 | (6.08) | 2.80 | 8.36 | 4.26 | 3.06 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.13 | 0.01 | 0.37 | 0.00 | 0.40 | 0.00 | 0.17 | 0.02 | 0.00 |
Operating CF/Net income |
2.39 | 1.03 | 0.58 | 0.85 | 0.68 | 1.43 | 0.76 | 1.70 | 0.39 | 0.59 |
Capex/Depreciation |
(3.26) | (2.58) | (0.79) | (1.41) | (1.66) | (4.55) | (1.54) | (0.48) | (0.10) | (0.05) |
Interest Coverage |
(8.46) | — | — | — | — | — | — | — | — | — |
| (22.75%) | (32.50%) | (56.89%) | 10.04% | (26.80%) | 18.59% | (30.42%) | (8.17%) | (19.20%) | (30.18%) | |
| (9.19%) | (22.18%) | (43.40%) | 8.59% | (24.10%) | 16.49% | (26.03%) | (6.87%) | (16.38%) | (25.81%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,148.27% | (699.33%) | (73.55%) | (1,032.08%) | 0.00% |
Return on Tangible Assets |
(7.26%) | (27.05%) | (36.09%) | 6.95% | (20.96%) | 15.51% | (34.30%) | (7.87%) | (18.47%) | (29.79%) |
Average Days of Receivables |
223.14 | 23.38 | 10.28 | 0.12 | 73.10 | 0.12 | 3,351.42 | 196.66 | 244.55 | 0.00 |
Research and Development Expense of Revenue |
817.93% | 170.26% | 3,641.90% | 61.94% | 37,127.40% | 37.22% | 38,534.64% | 104.34% | 831.42% | 10,856.38% |
Selling, General and Administrative Expense of Revenue |
601.39% | 87.43% | 1,545.90% | 21.92% | 12,268.15% | 10.90% | 8,552.92% | 20.52% | 195.58% | 2,095.21% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
209.99% | 46.04% | 1,119.88% | 15.21% | 9,181.92% | 11.19% | 8,175.88% | 21.83% | 232.00% | 2,065.50% |
Graham Net Nets |
0.75 | 0.16 | 0.27 | 0.26 | 0.15 | 0.36 | 0.47 | 0.30 | 0.49 | 0.35 |
Graham Number |
0.00 | 0.00 | 0.00 | 20.77 | 0.00 | 59.56 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(22.30%) | (6.83%) | (12.01%) | 1.82% | (3.44%) | 6.58% | (20.41%) | (2.94%) | (11.10%) | (12.43%) |
Free Cash Flow Yield |
(21.15%) | (7.73%) | (7.23%) | 1.51% | (2.54%) | 7.94% | (16.72%) | (5.16%) | (4.36%) | (7.34%) |
Revenue per Share |
0.42 | 1.02 | 0.07 | 5.32 | 0.01 | 12.05 | 0.02 | 4.69 | 0.44 | 0.04 |
Operating CF per Share |
(4.51) | (1.75) | (2.01) | 1.04 | (3.61) | 7.10 | (6.38) | (3.29) | (1.69) | (3.84) |
Capex per Share |
(0.25) | (0.20) | (0.06) | (0.12) | (0.28) | (1.08) | (0.48) | (0.12) | (0.02) | (0.01) |
Free Cash Flow per Share |
(4.76) | (1.94) | (2.06) | 0.92 | (3.89) | 6.02 | (6.85) | (3.41) | (1.71) | (3.85) |
Cash per Share |
25.74 | 5.99 | 9.52 | 17.35 | 25.63 | 31.33 | 23.35 | 21.38 | 22.57 | 21.97 |
Shareholders Equity per Share |
19.00 | 4.69 | 8.18 | 17.27 | 25.23 | 31.59 | 24.12 | 23.77 | 22.90 | 21.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
19.00 | 4.69 | 8.18 | 17.27 | 25.23 | 31.59 | 24.12 | 23.77 | 22.90 | 21.37 |
Free Cash Flow |
(58.33) | (77.91) | (99.01) | 49.99 | (256.72) | 457.27 | (532.93) | (269.84) | (144.67) | (345.93) |
Working Capital |
298.19 | 233.87 | 438.65 | 930.44 | 1,622.36 | 2,297.63 | 1,731.92 | 1,799.29 | 1,849.35 | 1,836.55 |
Capital Expenditures |
(3.02) | (7.81) | (2.77) | (6.68) | (18.36) | (81.70) | (37.19) | (9.47) | (1.90) | (0.91) |
Net Current Asset Value |
208.07 | 164.87 | 369.57 | 860.22 | 1,552.89 | 2,065.10 | 1,485.45 | 1,561.31 | 1,627.18 | 1,642.24 |
EV/EBIT |
0.58 | 0.00 | 0.00 | 51.63 | 0.00 | 9.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.58 | 0.19 | 0.89 | 0.02 | 25.53 | 0.09 | 31.04 | 0.03 | 0.05 | 0.26 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 70.88 | 0.00 | 15.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.04 | 0.16 | 0.19 | 0.15 | 0.26 | 0.13 | 0.15 | 0.13 | 0.14 | 0.17 |
Cash ROIC |
(10.64%) | (18.22%) | (11.66%) | 2.65% | (7.65%) | 9.57% | (14.44%) | (7.54%) | (3.77%) | (8.88%) |
Accounts Receivable Turnover |
2.95 | 14.18 | 2.30 | 3,097.22 | 5.92 | 4,075.56 | 0.21 | 3.52 | 0.33 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.75 | 2.89 | 1.36 | 0.09 | 0.12 | 0.22 | 5.65 | 105.50 | 112.50 | — |
Average Payables |
3.08 | 3.10 | 3.35 | 5.51 | 7.52 | 11.96 | 21.12 | 32.79 | 26.43 | 12.92 |
Average Assets |
252.19 | 308.15 | 380.18 | 777.88 | 1,447.36 | 2,289.92 | 2,497.47 | 2,236.31 | 2,235.80 | 2,253.64 |
Average Common Equity |
101.86 | 210.34 | 290.01 | 665.81 | 1,301.83 | 2,031.85 | 2,137.47 | 1,879.14 | 1,907.44 | 1,926.95 |
Columns are period end dates